Current Heart Failure Reports最新文献

Biomarkers of Hemodynamic Congestion in Heart Failure. 心力衰竭血流动力学充盈的生物标志物

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-19 DOI: 10.1007/s11897-024-00684-8

Alison Brann, Sean Selko, Ethan Krauspe, Kevin Shah

{"title":"Biomarkers of Hemodynamic Congestion in Heart Failure.","authors":"Alison Brann, Sean Selko, Ethan Krauspe, Kevin Shah","doi":"10.1007/s11897-024-00684-8","DOIUrl":"10.1007/s11897-024-00684-8","url":null,"abstract":"Purpose of review: The purpose of this review is to describe the evidence behind various blood and imaging-based biomarkers that can improve the identification of congestion when not clearly evident on routine examination.Recent findings: The natriuretic peptides (NPs) BNP and NT-proBNP have been shown to closely correlate with intra-cardiac filling pressures, both at baseline and when trended following improvement in congestion. Additionally, NPs rise well before clinical congestion is apparent so can be used as a tool to help identify subclinical HF decompensation. Additional serum-based biomarkers including MR-proANP and CA-125 can be helpful in assisting with diagnostic certainty when BNP or NT-proBNP are in the \"grey zone\" or when factors are present which may confound NP levels. Additionally, the emerging use of ultrasound techniques may enhance our ability to fine-tune the assessment and treatment of congestion. Biomarkers, including the blood-based natriuretic peptides and markers on bedside point of care ultrasound, can be used as non-invasive indices of hemodynamic congestion. These biomarkers are particularly valuable to incorporate when the degree of a patient's congestion is not apparent on clinical exam, and they can provide important prognostic information and help guide clinical management.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"541-553"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting Biomarkers of Cardiac Allograft Vasculopathy: Addressing the Achilles Heel of Heart Transplantation. 重新审视心脏移植血管病变的生物标志物：解决心脏移植的致命弱点。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-10-17 DOI: 10.1007/s11897-024-00685-7

Patrick E O'Hara, Ananya Gorrai, Maryjane Farr, Matthias Peltz, Hadi Beaini, Yasbanoo Moayedi, Sharon Chih, Lauren K Truby

{"title":"Revisiting Biomarkers of Cardiac Allograft Vasculopathy: Addressing the Achilles Heel of Heart Transplantation.","authors":"Patrick E O'Hara, Ananya Gorrai, Maryjane Farr, Matthias Peltz, Hadi Beaini, Yasbanoo Moayedi, Sharon Chih, Lauren K Truby","doi":"10.1007/s11897-024-00685-7","DOIUrl":"10.1007/s11897-024-00685-7","url":null,"abstract":"Nearly half of heart transplant recipients will be diagnosed with cardiac allograft vasculopathy (CAV) within five years after transplantation. Advanced CAV can lead to worsening heart failure as well as arrhythmias and sudden cardiac death. The only curative therapy for end-stage CAV is re-transplantation. Current diagnostic methods are invasive and limited by poor sensitivity in early disease. Despite its high prevalence in the post-transplantpopulation, the underlying pathophysiology of this condition has yet to be fully described. It is thought to be primarily related to endothelial dysfunction, immune activation, and cardiometabolic disease. Biomarkers reflecting these underlying processes, particularly endothelial injury and immune activation, have shown early promise in discriminating prevalent CAV. Next-generation sequencing technologies such as proteomic and transcriptomic profiling have also provided further insight into the pathophysiology of CAV through the identification of novel biomarkers. Ultimately, these biomarkers may have a role in not only diagnosing CAV but also highlighting potential targets for disease-specific therapies. In this article, we review the current data for biomarkers in CAV and discuss future directions for biomarker identification..","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"580-590"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population. 心力衰竭筛查：检测普通人群高风险的生物标志物。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-17 DOI: 10.1007/s11897-024-00686-6

Leah B Kosyakovsky, Rudolf A de Boer, Jennifer E Ho

{"title":"Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.","authors":"Leah B Kosyakovsky, Rudolf A de Boer, Jennifer E Ho","doi":"10.1007/s11897-024-00686-6","DOIUrl":"10.1007/s11897-024-00686-6","url":null,"abstract":"Purpose of review: Heart failure (HF) represents a growing global burden of morbidity and mortality. Identifying individuals at risk for HF development is increasingly important, particularly given the advent of disease-modifying therapies for HF as well as its major risk factors such as obesity actalnd diabetes. We aim to review the key circulating biomarkers associated with future HF which may contribute to HF risk prediction.Recent findings: While current guidelines recommend the use of natriuretic peptides and cardiac troponins in HF risk stratification, there are a diverse array of other emerging protein, metabolic, transcriptomic, and genomic biomarkers of future HF development. These biomarkers not only lend insight into the underlying pathophysiology of HF, which spans inflammation to cardiac fibrosis, but also offer an opportunity to further refine HF risk in addition to established biomarkers. As evolving techniques in molecular biology enable an increased understanding of the complex biologic contributions to HF pathophysiology, there is an important opportunity to construct integrated clinical and multi-omic models to best capture HF risk. Moving forward, future studies should seek to understand the contributions of sex differences, underlying comorbidity burden, and HF subtypes to an individual's HF risk. Further studies are necessary to fully define the clinical utility of biomarker screening approaches to refine HF risk assessment, as well as to link risk assessment directly to preventive strategies for HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"591-603"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications. 无症状癌症患者肌钙蛋白升高：揭示联系与临床意义

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-10 DOI: 10.1007/s11897-024-00681-x

Sebastian W Romann, Evangelos Giannitsis, Norbert Frey, Lorenz H Lehmann

引用次数: 0

Cardiogenic Shock: Focus on Non-Cardiac Biomarkers. 心源性休克：关注非心脏生物标志物。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-07-30 DOI: 10.1007/s11897-024-00676-8

Hadi Beaini, Zainali Chunawala, Daniel Cheeran, Faris Araj, Christopher Wrobel, Lauren Truby, Amit Saha, Jennifer T Thibodeau, Maryjane Farr

引用次数: 0

Genetic Biomarkers in Heart Failure: From Gene Panels to Polygenic Risk Scores. 心力衰竭的遗传生物标志物：从基因面板到多基因风险评分。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1007/s11897-024-00687-5

Marta Figueiral, Alessia Paldino, Luca Fazzini, Naveen L Pereira

{"title":"Genetic Biomarkers in Heart Failure: From Gene Panels to Polygenic Risk Scores.","authors":"Marta Figueiral, Alessia Paldino, Luca Fazzini, Naveen L Pereira","doi":"10.1007/s11897-024-00687-5","DOIUrl":"10.1007/s11897-024-00687-5","url":null,"abstract":"Purpose of review: This review aims to provide a comprehensive overview of the current understanding of genetic markers associated with heart failure (HF) and its underlying causative diseases, such as cardiomyopathies. It highlights the relevance of genetic biomarkers in diagnosing HF, predicting prognosis, potentially identifying its preclinical stages and identifying targets to enable the implementation of individualized medicine approaches.Recent findings: The prevalence of HF is increasing due to an aging population but with greater access to disease-modifying therapies. Advanced diagnostic tools such as cardiac magnetic resonance, nuclear imaging, and AI-enabled diagnostic testing are now being utilized to further characterize HF patients. Additionally, the importance of genetic testing in HF diagnosis and management is increasingly being recognized. Genetic biomarkers, including single nucleotide polymorphisms (SNPs) and rare genetic variants, are emerging as crucial tools for diagnosing HF substrates, determining prognosis and increasingly directing therapy. These genetic insights are key to optimizing HF management and delivering personalized treatment tailored to individual patients. HF is a complex syndrome affecting millions globally, characterized by high mortality and significant economic burden. Understanding the underlying etiologies of HF is essential for improving management and clinical outcomes. Recent advances highlight the use of multimodal assessments, including AI-enabled diagnostics and genetic testing, to better characterize and manage HF. Genetic biomarkers are particularly promising in identifying preclinical HF stages and providing personalized treatment options. The genetic contribution to HF is heterogeneous, with both monogenic and polygenic bases playing a role. These developments underscore the shift towards personalized medicine in HF management.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"554-569"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Failure in Rheumatoid Arthritis: Clinical Implications. 类风湿性关节炎的心力衰竭：临床意义。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-17 DOI: 10.1007/s11897-024-00682-w

Alexis Zambrano Zambrano, Hector Del Río Zanatta, Andrea González Espinoza, Brian Bernal Alferes, Kevin Zambrano Zambrano, Julio Martinez Salazar, Carlos Haroldo Ixcamparij Rosales

{"title":"Heart Failure in Rheumatoid Arthritis: Clinical Implications.","authors":"Alexis Zambrano Zambrano, Hector Del Río Zanatta, Andrea González Espinoza, Brian Bernal Alferes, Kevin Zambrano Zambrano, Julio Martinez Salazar, Carlos Haroldo Ixcamparij Rosales","doi":"10.1007/s11897-024-00682-w","DOIUrl":"10.1007/s11897-024-00682-w","url":null,"abstract":"Purpose of review: This review focuses on the association between RA and heart failure, highlighting the role of inflammation and the prevalence of heart failure with preserved ejection fraction (HFpEF) in this population.Recent findings: The incidence of heart failure in RA patients is two to three times higher than in the general population, with inflammation playing a significant role independent of traditional cardiovascular risk factors. HFpEF accounts for about half of heart failure cases and is increasingly recognized in RA patients, although it remains underdiagnosed. Atypical presentations and non-specific symptoms further complicate diagnosis. Early control of inflammation has been shown to reduce the risk of heart failure development and progression, improving both morbidity and mortality outcomes. Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting approximately 1% of the population, with cardiovascular disease being the leading cause of premature death in these patients.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"530-540"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Biomarkers in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies. 心脏肉样瘤病和其他炎症性心肌病的新生物标志物

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI: 10.1007/s11897-024-00683-9

Joseph El Roumi, Ziad Taimeh

{"title":"Emerging Biomarkers in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies.","authors":"Joseph El Roumi, Ziad Taimeh","doi":"10.1007/s11897-024-00683-9","DOIUrl":"10.1007/s11897-024-00683-9","url":null,"abstract":"Purpose of review: Cardiac sarcoidosis and other inflammatory cardiomyopathies are disorders causing cardiac inflammation and leading to heart failure, arrythmias and cardiac arrest. Diagnosis of these entities remains challenging and multimodal. Thus, there is a growing need to develop reliable biomarkers that can aid in the diagnosis. This review aims to summarize and highlight recent findings in the field of biomarkers for cardiac sarcoidosis and inflammatory cardiomyopathy.Recent findings: Multiple categories of biomarkers including novel molecules are being investigated with the latest evidence showing promising results. Some of these biomarkers are proven to be useful as diagnostic and prognostic aids in cardiac sarcoid and inflammatory cardiomyopathy. The identification of cost-effective and accurate biomarkers is useful not only for enhancing diagnostic accuracy but also for informing therapeutic decision-making processes. This advancement would facilitate the timely institution of immunosuppressive therapies, ultimately leading to improved patient outcomes.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"570-579"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer Development and Progression in Patients with Heart Failure. 心力衰竭患者的癌症发展与恶化

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-28 DOI: 10.1007/s11897-024-00680-y

Katharina Seuthe, Felix Simon Ruben Picard, Holger Winkels, Roman Pfister

{"title":"Cancer Development and Progression in Patients with Heart Failure.","authors":"Katharina Seuthe, Felix Simon Ruben Picard, Holger Winkels, Roman Pfister","doi":"10.1007/s11897-024-00680-y","DOIUrl":"10.1007/s11897-024-00680-y","url":null,"abstract":"Purpose of review: The co-occurrence of heart failure (HF) and cancer represents a complex and multifaceted medical challenge. Patients with prevalent cardiovascular disease (CVD), particularly HF, exhibit an increased risk of cancer development, raising questions about the intricate interplay between these two prevalent conditions. This review aims to explore the evolving landscape of cancer development in patients with HF, shedding light on potential mechanisms, risk factors, and clinical implications.Recent findings: Epidemiological data suggests higher cancer incidences and higher cancer mortality in HF patients, which are potentially more common in patients with HF with preserved ejection fraction due to related comorbidities. Moreover, recent preclinical data identified novel pathways and mediators including the protein SerpinA3 as potential drivers of cancer progression in HF patients, suggesting HF as an individual risk factor for cancer development. The review emphasizes preliminary evidence supporting cancer development in patients with HF, which offers several important clinical interventions such as cancer screening in HF patients, prevention addressing both HF and cancer, and molecular targets to treat cancer. However, there is need for more detailed understanding of molecular and cellular cross-talk between cancer and HF which can be derived from prospective assessments of cancer-related outcomes in CV trials and preclinical research of molecular mechanisms.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"515-529"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities. 心力衰竭中的心房颤动：新的见解、挑战和治疗机会。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-11-22 DOI: 10.1007/s11897-024-00691-9

Ghassan Bidaoui, Ala' Assaf, Nassir Marrouche

引用次数: 0